← Back to Search

Blood Flow Restriction Training for ACL Reconstruction Recovery

N/A
Recruiting
Led By Adam Weaver, PT, DPT
Research Sponsored by Connecticut Children's Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Orthopedic surgical intervention and physical therapy completed at Connecticut Children's
Be younger than 65 years old
Must not have
Inability to attend regular physical therapy sessions (≥80% of patient treatment sessions and all assessment visits
Contraindications to performing BFRT including known history of central or peripheral neurologic impairments, cardiac or metabolic condition or history of deep vein thrombosis (DVT)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change in strength at pre-op, 8 weeks, 3months post-op, 6months, 9 months post-op
Awards & highlights
No Placebo-Only Group

Summary

This trial will evaluate if adding a BFRT-based exercise program to a standard ACLR rehab protocol improves outcomes in adolescents.

Who is the study for?
This trial is for adolescents who have had ACL reconstruction and were active in sports before their injury. They must have completed surgery and physical therapy at Connecticut Children's, following standard protocols, without other major knee injuries or surgeries, weight bearing restrictions over 4 weeks due to additional pathology, or follow-up procedures like arthrofibrosis.
What is being tested?
The study tests if adding Blood Flow Restriction Training (BFRT) using the Delfi Personalized Tourniquet System to standard ACL rehab improves strength, muscle growth, and patient outcomes in adolescents after ACL reconstruction compared to just the standard rehab protocol.
What are the potential side effects?
Potential side effects of BFRT may include discomfort from the tourniquet system used to restrict blood flow during exercise. There could also be risks related to exacerbation of existing conditions such as neurologic impairments or a history of deep vein thrombosis.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I completed orthopedic surgery and physical therapy at Connecticut Children's.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot attend most of my physical therapy sessions.
Select...
I do not have neurological, heart conditions, or a history of DVT that would prevent BFRT.
Select...
I must limit putting weight on my leg for over 4 weeks after surgery due to other knee issues.
Select...
I have another leg injury or had surgery on either knee.
Select...
I am scheduled for or have had surgery that might require follow-up for stiffness.
Select...
I have had multiple ligament injuries.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change in strength at pre-op, 8 weeks, 3months post-op, 6months, 9 months post-op
This trial's timeline: 3 weeks for screening, Varies for treatment, and change in strength at pre-op, 8 weeks, 3months post-op, 6months, 9 months post-op for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Isokinetic Hamstring Strength limb symmetry index
Isokinetic Hamstrings Strength
Isokinetic Quadriceps Strength limb symmetry index
+6 more
Secondary study objectives
Anterior Cruciate Ligament- Return to Sport after Injury
Knee Outcomes and Osteoarthritis Scale
Pediatric International Knee Documentation Committee
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: BFR Intervention GroupExperimental Treatment1 Intervention
In addition to the standard ACL rehabilitation protocol, the experimental group will complete 2 exercises using the Delfi BFR cuff 2x/week for 8 weeks during their treatment session at Connecticut Children's Sports Physical Therapy on the second post-operative visit. Cuff size will be determined by patient thigh circumference Limb occlusion pressure will be determined in supine position and all exercises will be completed at 80% occlusion. Long Arc Quadriceps (LAQ) progression Shuttle progression Post-op visit 2- 2 weeks Quadriceps Set Standing Straight Leg Raise 2 weeks-4 weeks Available range LAQ Standing terminal knee extension 4 weeks-8 weeks LAQ (0-90°) Single Limb Shuttle/Leg Press
Group II: No Intervention/Control GroupActive Control1 Intervention
In addition to the standard ACL rehabilitation protocol, the control group will complete the same exercises as the experimental group starting on the second post-operative visit. Long Arc Quadriceps (LAQ) progression Shuttle progression Post-op visit 2- 2 weeks Quadriceps Set Standing Straight Leg Raise 2 weeks-4 weeks Available range LAQ Standing terminal knee extension 4 weeks-8 weeks LAQ (0-90°) Single Limb Shuttle/Leg Press
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Blood Flow Restriction using Delfi Personalized Tourniquet System
2020
N/A
~50

Find a Location

Who is running the clinical trial?

Connecticut Children's Medical CenterLead Sponsor
73 Previous Clinical Trials
26,584 Total Patients Enrolled
University of ConnecticutOTHER
190 Previous Clinical Trials
160,823 Total Patients Enrolled
1 Trials studying Anterior Cruciate Ligament Injury
129 Patients Enrolled for Anterior Cruciate Ligament Injury
Adam Weaver, PT, DPTPrincipal InvestigatorPhysical Therapist
1 Previous Clinical Trials
47 Total Patients Enrolled

Media Library

BFR Intervention Group Clinical Trial Eligibility Overview. Trial Name: NCT05754632 — N/A
Anterior Cruciate Ligament Injury Research Study Groups: BFR Intervention Group, No Intervention/Control Group
Anterior Cruciate Ligament Injury Clinical Trial 2023: BFR Intervention Group Highlights & Side Effects. Trial Name: NCT05754632 — N/A
BFR Intervention Group 2023 Treatment Timeline for Medical Study. Trial Name: NCT05754632 — N/A
~9 spots leftby May 2025